The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AGILE THERAPEUTICS, INC. | Common Stock | 00847L100 | 718 | 1,958,875 | SH | SOLE | 1,958,875 | 0 | 0 | ||
| AGILE THERAPEUTICS, INC. | Common Stock | 00847L100 | 1,137 | 3,103,488 | SH | DFND | 1 | 3,103,488 | 0 | 0 | |
| IMMUNE DESIGN CORP. | Common Stock | 45252L103 | 4,266 | 1,236,394 | SH | SOLE | 1,236,394 | 0 | 0 | ||
| MERSANA THERAPEUTICS, INC. | Common Stock | 59045L106 | 9,557 | 955,709 | SH | DFND | 1 | 955,709 | 0 | 0 | |
| UROGEN PHARMA LTD. | Common Stock | M96088105 | 37,278 | 789,297 | SH | SOLE | 789,297 | 0 | 0 | ||